1 |
Ferlay J, Soerjomataram I, Ervik M, et al (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer.
|
2 |
Eskander RN, Tewari KS (2014). Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer. Curr Opin Obstet Gynecol, 26, 314-21
DOI
|
3 |
Kaern J, Trope C, Sundfoer K, et al (1996). Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. Gynecol Oncol, 60, 387-92.
DOI
|
4 |
Kamura T, Ushijima K (2013). Chemotherapy for advanced or recurrent cervical cancer. Taiwan J Obstet Gynecol, 52, 161-4.
DOI
|
5 |
Kitagawa R, Katsumata N, Shibata T, et al (2015). Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol, 33, 2129-35.
DOI
|
6 |
Long HJ 3rd, Bundy BN, Grendys EC Jr, et al (2005). Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol, 23, 4626-33.
DOI
|
7 |
Moore DH, Blessing JA, McQuellon RP, et al (2004). Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol, 22, 3113-9.
DOI
|
8 |
Monk BJ, Sill MW, McMeekin DS, et al (2009). Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study. J Clin Oncol, 27, 4649-55.
DOI
|
9 |
Moore DH, Tian C, Monk BJ, et al (2010). Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol, 116, 44-9.
DOI
|
10 |
Micha JP, Sassoon AF, Wong H, et al (2015). Prolonged remission of recurrent cervical carcinoma following paclitaxel and carboplatin chemotherapy with paclitaxel maintenance chemotherapy. Anticancer Drugs, 26, 793-6.
DOI
|
11 |
Mackay HJ, Wenzel L, Mileshkin L(2015). Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond. Am Soc Clin Oncol Educ Book, 299-309.
|
12 |
Peiretti M, Zapardiel I, Zanagnolo V, et al (2012). Management of recurrent cervical cancer: a review of the literature. Surg Oncol, 21, 59-66.
DOI
|
13 |
Pfaendler KS, Tewari KS (2016). Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol, 214, 22-30.
DOI
|
14 |
Tewari KS, Sill MW, Long HJ 3rd, et al (2014). Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med, 370, 734-43.
DOI
|